Drug Database
TE

teriparatide (Osteoform / Osteotide)

✓ Approved

Virchow Biotech · PTH1R · Recombinant Proteins

What is teriparatide?

teriparatide is a recombinant proteins developed by Virchow Biotech. It is approved for therapeutic indications via injectable (others) or subcutaneous injection.

Drug Profile

Brand NamesOsteoform, Osteotide
CompanyVirchow Biotech
Drug ClassRecombinant Proteins
Molecular TargetPTH1R
RouteInjectable (Others), Subcutaneous Injection
StatusApproved
Sources: ClinicalTrials.gov, Virchow Biotech

Mechanism of Action

Molecular Targets

teriparatide acts on 1 molecular target:

PTH1Rparathyroid hormone 1 receptor (PTHR, EKNS)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

teriparatide is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Musculoskeletal and connective tissue disordersOsteoporosis✓ Approved

Related Research Articles

PubMedFrontiers in pharmacology2026-11-10

Therapeutic potential of hydroxybenzoic acid and lentinan in mitigating glucocorticoid-induced osteoporosis: an experimental study.

Soyler Busra B, Parlak Tugba Melike TM, Buyuktaskapulu Ibrahim I, Demircioglu Muhammed M et al.

The present study aimed to elucidate the therapeutic efficacy and mechanistic roles of Hydroxybenzoic Acid and Lentinan in counteracting glucocorticoid-induced osteoporosis (GIOP) in mice, with a focus on bone metabolism, inflammation, and oxidative stress pathways. Sixty-eight male Swiss Albino mice were randomly assigned to seven groups: Healthy Control, Osteoporosis (methylprednisolone 10 mg/kg), Teriparatide (3 μg/kg), Low-Dose Lentinan (200 mg/kg), High-Dose Lentinan (400 mg/kg), Low-Dose HBA (50 μg/kg), and High-Dose HBA (100 μg/kg). In the study, all treatments were administered daily for a duration of 10 weeks. Methylprednisolone administration resulted in marked deterioration of bone quality, with significant reductions in 25(OH)D3, IGF-1, and increased osteocalcin, TNF-α, IL-1β, HSP-27, RANK, and RANKL expression, accompanied by severe trabecular bone loss, all treatment groups showed notable recovery, with the most pronounced restoration in teriparatide and high-dose hydroxybenzoic acid groups. Mechanistically, hydroxybenzoic acid exerted potent anti-osteoclastic effects through RANK/RANKL pathway suppression, while Lentinan enhanced osteoblastic activity and mitigated inflammatory damage. In conclusion, these results provide preclinical evidence that HBA and lentinan warrant further investigation as potential adjuncts to established anti-osteoporotic therapy in the setting of long-term glucocorticoid use.

PMID 43005257
Read full article →
PubMedJournal of medical case reports2026-11-09

Atraumatic subtrochanteric femoral fracture nonunion with suspected impairment of bone quality despite preserved bone mineral density: a case report.

Nozaka Koji K, Miyakoshi Naohisa N

Fracture nonunion is a multifactorial condition involving both mechanical and biological factors. We report a case of atraumatic subtrochanteric femoral fracture nonunion in a patient with relatively preserved bone mineral density (BMD) and biochemical findings suggestive of possible impairment of bone material properties. A 64-year-old man developed a subtrochanteric femoral fracture without an identifiable traumatic event and underwent intramedullary nailing. Despite dynamization, symptomatic nonunion persisted 11 months after surgery. Metabolic evaluation identified chronic kidney disease and vitamin D deficiency. Femoral BMD was 0.854 g/cm2 and lumbar spine BMD was 1.599 g/cm2. Plasma homocysteine and urinary pentosidine were markedly elevated at 20.1 nmol/mL and 0.2101 μg/mg·Cre, respectively. These surrogate biomarkers raised suspicion of impaired bone material properties but did not directly demonstrate impaired bone quality. The local mechanical environment was not quantitatively assessed, and mechanical inadequacy could not be excluded. Revision surgery was considered; however, because of the patient's comorbidities and the anticipated invasiveness of surgery, an initial individualized strategy using concurrent daily teriparatide and low-intensity pulsed ultrasound was selected with close monitoring. Radiographic union was observed approximately 5 months after treatment initiation and remained maintained at 13-year follow-up. Because both interventions were initiated concurrently, their individual and combined contributions to fracture healing could not be determined. This case highlights the importance of assessing both mechanical and biological factors in established nonunion, particularly when an atraumatic fracture occurs despite relatively preserved BMD. Revision surgery with mechanical optimization remains the standard of care. The observed union does not establish the efficacy of teriparatide, low-intensity pulsed ultrasound, or their combination, and the management used in this patient should be interpreted as an individualized strategy rather than a validated alternative to revision surgery.

PMID 43000416
Read full article →
PubMedBMC musculoskeletal disorders2026-11-08

Perioperative teriparatide use in osteopenic and osteoporotic patients undergoing multi- and long-segment posterior spinal fusion.

Steele Lucas L, Kadri Aamir A, Abdollahifard Saeed S, Kothari Dhruv D et al.

Osteoporosis and osteopenia are common in spine surgical patients and are associated with adverse outcomes. Perioperative Teriparatide use improves bone quality and decreases the risk of adverse events. We hypothesized that teriparatide use before and after long-segment posterior spinal fusion (PSF) would decrease the rate of adverse surgical events, including pseudoarthrosis, secondary fracture, and revision surgery, in osteoporotic and osteopenic patients compared to patients in a non-osteoporotic, non-teriparatide group. Between 2016 and 2020, 58 adult patients who underwent long-segment PSF were included. The cases (n = 17) were patients with osteoporosis or osteopenia who received a minimum of six weeks of pre- and at least six months of post-operative teriparatide treatment. The control group (n = 41) included patients without osteoporosis who did not require teriparatide treatment. Cases and controls were matched based on surgery type, surgical levels, and follow-up length. The minimum follow-up time was 12 months. The mean age was 69.0 in the cases vs. 65.4 years in the control group. There were no significant differences based on age, body mass index, gender, race, history of diabetes, history of steroid use, or tobacco usage between the 2 groups. The number of fused vertebral levels and interbody cages placed did not significantly differ either, with 7.8 vs. 6.4 fused levels (p-value = 0.06) and 0.7 interbodies vs. 0.3 interbodies (p-value = 0.15) for the cases and controls, respectively. The case group experienced a higher rate of extension into the pelvis (47.1% vs. 17.1%, p-value = 0.03). The rates of pseudarthrosis (29.4% vs. 17.1%, p-value = 0.31) and reoperation rate (23.5% vs. 17.1%, p-value = 0.72) were not statistically different for the case or control groups, respectively. No postoperative fractures were observed. Teriparatide use resulted in similar postoperative outcomes in the case group compared to the control group in patients undergoing long-segment PSF despite a less favorable baseline in the case group, including the presence of osteoporosis and fusion that required extension into the pelvis. Given the retrospective observational design and absence of an untreated osteopenic/osteoporotic comparison group, these findings should be interpreted as exploratory and hypothesis-generating. Further prospective studies are needed to determine whether teriparatide independently influences outcomes after long-segment spinal fusion.

PMID 42995581
Read full article →
PubMedJournal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research2026-11-08

Investigating Factors Influencing the Long-Term Outcome of Teriparatide Treatment on the Risk of Hip Fracture. Is sequential treatment essential?

Meszaros Szilvia S, Szili Balazs B, Szabo Boglarka B, Nemeth Zsuzsanna Z et al.

Teriparatide (TPTD) is an anabolic therapy for severe osteoporosis. Clinical trials have shown its efficacy in reducing vertebral and non-vertebral fractures, data on hip fracture prevention in real-world settings and the impact of sequential antiresorptive (AR) therapy remain limited. We conducted a retrospective cohort study using the Hungarian National Health Insurance Database, which covers the entire population (~9.7 million). Patients with osteoporosis who received TPTD between 2010 and 2023, with treatment initiated by January 1, 2022. Hip fractures were tracked from day 180 after TPTD initiation for up to five years. Adherence was assessed via medication possession ratio. Post-TPTD AR therapy (bisphosphonate or denosumab) and the timing of its initiation were evaluated as factors influencing hip fracture risk. Poisson regression models were applied, adjusting for demographics, prior fractures, and healthcare utilization. Among 8,893 eligible patients, 574 hip fractures occurred during follow-up. High adherence was associated with reduced hip fracture risk by 20% (p<0.05). The number of fractures prior to treatment was also associated with fracture risk, increasing it by 11% (p<0.05). Delayed AR initiation was closely related to a proportional increase in risk, which grew proportionally with the time elapsed between the two treatments. In a cohort of patients exhibiting high adherence, deferring AR treatment for over 90 days post-TPTD therapy was associated with an increase of 19% in hip fracture risk when subsequent treatment involved bisphosphonates, and a 31% increase when denosumab was utilized as the follow-up therapy. The efficacy of teriparatide treatment was associated with patient adherence and the number of prior fractures. Neglecting to initiate AR treatment following teriparatide therapy, or starting it late, was strongly linked to an increased risk of hip fractures. Our findings provide real-world data supporting timely initiation of AR therapy post-TPTD for sustained fracture prevention.

PMID 42999936
Read full article →
PubMedOphthalmology2026-11-04

Short-term Risk of Inflammatory Eye Reactions Following Bisphosphonate Use: A nationwide case-case-time-control study.

Hsing-Chun Hsieh Miyuki M, Chun-Yuan Cheng Michael M, Shao Shih-Chieh SC, Hung Jia-Horung JH et al.

To evaluate short-term associations between bisphosphonate exposure and uveitis, scleritis, and cystoid macular edema (CME). Nationwide case-case-time-control (CCTC) study. Patients with incident uveitis, scleritis, or CME identified from Taiwan's national health claims data (2011-2021), with matched future cases serving as controls to adjust for temporal exposure trends. Bisphosphonate exposure during the 30-day hazard window immediately preceding each event was compared with exposure during an earlier 30-day reference window, separated by a 90-day washout period. Each case was matched to a future case to account for temporal trends in bisphosphonate use. Analyses were stratified by administration route and individual agent. Sensitivity analyses varied window lengths, washout periods, and lag structures. Denosumab and teriparatide served as negative-control exposures. Incident uveitis, scleritis, and CME, with associations quantified using CCTC odds ratios (ORs) and 95% confidence intervals (CIs). We identified 269,545 incident uveitis cases, 132,585 scleritis cases, and 115,914 CME cases; over 96% were matched to a future case and included in CCTC analyses. After accounting for exposure trends, any bisphosphonate use was associated with an increased short-term risk of uveitis (OR, 1.24; 95% CI, 1.00-1.56), driven primarily by anterior uveitis (OR 1.43; 95% CI, 1.10-1.86). In analyses stratified by administration route and individual agent, intravenous bisphosphonates (OR, 1.78; 95% CI, 1.22-2.61), particularly zoledronic acid (OR, 2.82; 95% CI, 1.70-4.67), were associated with increased uveitis risk. Oral bisphosphonates were not associated with uveitis (OR, 0.99; 95% CI, 0.74-1.33). No clear associations were observed for scleritis or CME. Findings were consistent across subgroup and sensitivity analyses, and associations for negative-control exposures were null. Short-term associations between bisphosphonate use and ocular inflammatory events varied by administration route and outcome. Increased uveitis risk was concentrated among intravenous formulations, particularly zoledronic acid, whereas no clear associations were found for scleritis or CME. These findings may inform monitoring for ocular symptoms among patients receiving intravenous bisphosphonates.

PMID 42982279
Read full article →
PubMedClinical epidemiology2026-11-03

Cardiovascular Events Among Female Users of Osteoporosis Treatments: A Cohort Study in United Kingdom Primary Care Data.

Persson Rebecca R, Yang Tzu-Hsuan TH, Jafry Zarena Z, Vasilakis-Scaramozza Catherine C et al.

Information on cardiovascular disease (CVD) safety of osteoporosis treatments is important for patients and clinicians choosing between treatment options. We conducted a cohort study in the United Kingdom Clinical Practice Research Datalink Aurum and linked inpatient data (2000-2020). We selected two cohorts of female patients aged 40-89 with no history of CVD: (1) treated cohort: new users of study drugs (alendronate, ibandronate, risedronate, zoledronic acid, etidronate, denosumab, raloxifene, teriparatide, and calcitonin); (2) common reference cohort: prescription vitamin D users with a diagnosis or monitoring for osteoporotic disease. We followed patients from first prescription through censor date (event, major comorbidity, age 90, or end of record) and estimated adjusted incidence rate ratios (aIRRs) of atrial fibrillation (AFib), myocardial infarction (MI), stroke, and fatal stroke, by study drug compared to vitamin D-only. We assessed aIRRs compared to the common referent across all osteoporosis treatments. Among 226,484 (74%) patients in the treated cohort and 79,973 (26%) in the vitamin D-only referent cohort, there were 4313 AFib, 7312 stroke, and 3846 MI outcomes. AFib rates were highest in zoledronic acid users (13 outcomes; aIRR 1.87; 95% CI 1.08-3.24). MI incidence was highest among ibandronate users (63 outcomes; aIRR 1.50; 95% CI 1.16-1.95). There were no differences in rates of AFib or MI across other study drugs or for stroke or fatal stroke for any study drug. Rates of AFib, MI and stroke were similar across most osteoporosis treatments, including between various types of bisphosphonates. However, the rate of AFib was increased among zoledronic acid users and rate of MI was somewhat increased among ibandronate users. However, findings were generally limited by small numbers of exposed outcomes.

PMID 42974095
Read full article →

+2933 more articles available with a free account

Sign up free to view all articles →

Ask about teriparatide